As obesity has become a global public health challenge, the conventional advice of “diet control and exercise” is difficult for many to sustain over the long term. Scientists are now turning to the body’s internal “invisible organ”—the gut microbiome—in search of novel approaches to weight management.
A patent invention from Ocean University of China reveals the potential of a probiotic strain, Lactobacillus plantarum F3-2, in ameliorating obesity. This study not only validates its efficacy but also elucidates the underlying molecular mechanisms, providing new scientific evidence for microbiome-based weight management interventions.
Strain Screening: Viability as a Prerequisite for Efficacy
For any orally administered probiotic to exert its effects, the primary prerequisite is its ability to withstand gastric acid and bile salts, survive the digestive tract, and colonize the gut.
In vitro experimental data from the patent demonstrate the remarkable tolerance of L. plantarum F3-2:
- ✓ Acid resistance: After 3 hours of exposure to strong acid at pH 3.0, the survival rate reached 97.23%.
- ✓ Bile salt resistance: After 4 hours of exposure to 0.3% bile salts, the survival rate remained 87.61%.
- ✓ Simulated gastrointestinal fluid tolerance: After sequential treatment with simulated gastric and intestinal fluids, the final survival rate remained as high as 86.16%.
These data indicate that strain F3-2 possesses the “hard power” to serve as an effective oral probiotic formulation, laying the foundation for its subsequent in vivo functionality.
Model Experiments: Weight-Loss Effects Comparable to Drugs
To verify its in vivo efficacy, researchers employed a classic high-fat diet (HFD)-induced obese mouse model with four experimental groups:
After 8 weeks of intervention, mice in the F3-2 group exhibited multifaceted positive changes.
Body weight and fat control: Compared with the HFD group, the F3-2 group showed significantly slower body-weight gain. More importantly, the weight of epididymal fat—a key indicator of visceral fat—was markedly reduced, with effects comparable to those of the orlistat group. Meanwhile, F3-2 also significantly alleviated the liver weight gain induced by the high-fat diet.
Improved adipocyte morphology: Microscopic observation revealed that adipocytes in the HFD group were significantly enlarged, whereas F3-2 intervention markedly reduced cell size, with morphology approaching that of the normal control group. This indicates that F3-2 effectively alleviates adipocyte hypertrophy.
Regulation of blood lipid levels: F3-2 intervention led to a 42.14% reduction in serum triglyceride (TG) levels, with the improvement being not significantly different from that of the orlistat group (41.41% decline).
Mechanistic Exploration: A Clear “Gut–Adipose Axis” Pathway
The core value of this study lies in its clear elucidation of the molecular pathway through which L. plantarum F3-2 exerts its effects—namely, the SCFAs–GPR43–PPARγ axis.
Regulation of metabolites: The study found that F3-2 intervention significantly increased the levels of short-chain fatty acids (SCFAs), particularly acetic acid, in the feces of obese mice. SCFAs are key metabolites produced by gut microbiota fermentation of dietary fiber and serve as important signaling messengers between the microbiota and the host.
Activation of adipose tissue receptors: The increased acetic acid and other SCFAs activate a specific receptor on the surface of adipose tissue cells—GPR43 (also known as FFAR2). Experimental data showed that GPR43 gene expression in the adipose tissue of F3-2 group mice was significantly restored.
Suppression of adipogenic genes: Upon activation, GPR43 transmits downstream signals that significantly suppress the expression of PPARγ—the “master switch” in adipogenesis. PPARγ is the core transcription factor regulating the differentiation of preadipocytes into mature adipocytes; its reduced expression indicates that fat synthesis and storage are effectively curtailed.
In summary, the mechanism of action can be outlined as follows:
Lactobacillus plantarum F3-2 → Increases intestinal SCFAs (especially acetate) → Activates the GPR43 receptor on adipose tissue → Suppresses the key adipogenic factor PPARγ → Reduces fat synthesis and accumulation → Improves body weight and body fat.
